董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Carl Gordon | 男 | Independent Director | 60 | 未披露 | 未持股 | 2025-10-15 |
| Jasbir Seehra | 男 | President, Chief Executive Officer and Director | 70 | 69.45万美元 | 未持股 | 2025-10-15 |
| Nima Farzan | 男 | Independent Director | 49 | 未披露 | 未持股 | 2025-10-15 |
| Julius Knowles | 男 | Independent Director | 61 | 未披露 | 未持股 | 2025-10-15 |
| Jean Jacques Bienaime | -- | Chair | -- | 未披露 | 未持股 | 2025-10-15 |
| Mary Ann Gray | -- | Independent Director | -- | 未披露 | 未持股 | 2025-10-15 |
| Alpna Seth | -- | Independent Director | -- | 未披露 | 未持股 | 2025-10-15 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jasbir Seehra | 男 | President, Chief Executive Officer and Director | 70 | 69.45万美元 | 未持股 | 2025-10-15 |
| Keith Regnante | 男 | Chief Financial Officer and Principal Accounting Officer | 55 | 未披露 | 未持股 | 2025-10-15 |
| Lorena Lerner | 女 | Chief Scientific Officer | 54 | 未披露 | 未持股 | 2025-10-15 |
| Esther Cho | 女 | Senior Vice President, General Counsel | 36 | 未披露 | 未持股 | 2025-10-15 |
董事简历
中英对照 | 中文 | 英文- Carl Gordon
-
Carl Gordon，自2020年7月起担任Mbx Biosciences, Inc.董事会成员。他曾担任OrbiMed Advisors LLC（一家投资公司）的创始成员、管理合伙人和全球私募股权联席主管（1998年以来）。他目前担任Adicet Bio, Inc.（纳斯达克代码：ACET）， ArriVent Biopharma Inc.（纳斯达克代码：AVBP）， Compass Therapeutics, Inc.（纳斯达克代码：CMPX）， Keros Therapeutics, Inc.（纳斯达克代码：KROS）和Terns Pharmaceuticals, Inc.（纳斯达克代码：TERN）以及几家私人公司的董事会成员。他曾任职于Alector, Inc.（纳斯达克代码：ALEC）， Gemini Therapeutics, Inc.（前纳斯达克代码：GMTX，与Disc Medicine, Inc.合并），Kinnate Biopharma Inc.（纳斯达克代码：KNTE）， ORIC Pharmaceuticals, Inc.（纳斯达克代码：ORIC）， Passage Bio, Inc.（纳斯达克代码：PASG）， precintics Inc.（前纳斯达克代码：PRVL，被Eli Lilly收购），SpringWorks Therapeutics, Inc.（纳斯达克代码：SWTX）， Theseus Pharmaceuticals, Inc.（前纳斯达克代码：SWTX）的董事会。THRX（被Concentra Biosciences LLC收购）和Turning Point Therapeutics, Inc.（前纳斯达克股票代码：TPTX，被Bristol Myers Squibb Co.收购）。他持有Harvard College的化学学士学位，Massachusetts Institute of Technology的分子生物学博士学位，也是the Rockefeller University的研究员。
Carl Gordon,has served on Mbx Biosciences, Inc. board of directors since July 2020. He has served as a founding member, Managing Partner, and Co-Head of Global Private Equity at OrbiMed Advisors LLC, an investment firm, since 1998. Dr. Gordon currently serves on the boards of directors of Adicet Bio, Inc. (Nasdaq: ACET), ArriVent Biopharma Inc. (Nasdaq: AVBP), Compass Therapeutics, Inc. (Nasdaq: CMPX), Keros Therapeutics, Inc. (Nasdaq: KROS), and Terns Pharmaceuticals, Inc. (Nasdaq: TERN), as well as several private companies. Dr. Gordon previously served on the boards of Alector, Inc. (Nasdaq: ALEC), Gemini Therapeutics, Inc. (formerly Nasdaq: GMTX which merged with Disc Medicine, Inc.), Kinnate Biopharma Inc. (Nasdaq: KNTE), ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), Passage Bio, Inc. (Nasdaq: PASG), Prevail Therapeutics Inc. (formerly Nasdaq: PRVL which was acquired by Eli Lilly), SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), Theseus Pharmaceuticals, Inc. (formerly Nasdaq: THRX which was acquired by Concentra Biosciences LLC), and Turning Point Therapeutics, Inc. (formerly Nasdaq: TPTX which was acquired by Bristol Myers Squibb Co.). Dr. Gordon received his B.A. in Chemistry from Harvard College, his Ph.D. in Molecular Biology from the Massachusetts Institute of Technology, and was a Fellow at The Rockefeller University. - Carl Gordon，自2020年7月起担任Mbx Biosciences, Inc.董事会成员。他曾担任OrbiMed Advisors LLC（一家投资公司）的创始成员、管理合伙人和全球私募股权联席主管（1998年以来）。他目前担任Adicet Bio, Inc.（纳斯达克代码：ACET）， ArriVent Biopharma Inc.（纳斯达克代码：AVBP）， Compass Therapeutics, Inc.（纳斯达克代码：CMPX）， Keros Therapeutics, Inc.（纳斯达克代码：KROS）和Terns Pharmaceuticals, Inc.（纳斯达克代码：TERN）以及几家私人公司的董事会成员。他曾任职于Alector, Inc.（纳斯达克代码：ALEC）， Gemini Therapeutics, Inc.（前纳斯达克代码：GMTX，与Disc Medicine, Inc.合并），Kinnate Biopharma Inc.（纳斯达克代码：KNTE）， ORIC Pharmaceuticals, Inc.（纳斯达克代码：ORIC）， Passage Bio, Inc.（纳斯达克代码：PASG）， precintics Inc.（前纳斯达克代码：PRVL，被Eli Lilly收购），SpringWorks Therapeutics, Inc.（纳斯达克代码：SWTX）， Theseus Pharmaceuticals, Inc.（前纳斯达克代码：SWTX）的董事会。THRX（被Concentra Biosciences LLC收购）和Turning Point Therapeutics, Inc.（前纳斯达克股票代码：TPTX，被Bristol Myers Squibb Co.收购）。他持有Harvard College的化学学士学位，Massachusetts Institute of Technology的分子生物学博士学位，也是the Rockefeller University的研究员。
- Carl Gordon,has served on Mbx Biosciences, Inc. board of directors since July 2020. He has served as a founding member, Managing Partner, and Co-Head of Global Private Equity at OrbiMed Advisors LLC, an investment firm, since 1998. Dr. Gordon currently serves on the boards of directors of Adicet Bio, Inc. (Nasdaq: ACET), ArriVent Biopharma Inc. (Nasdaq: AVBP), Compass Therapeutics, Inc. (Nasdaq: CMPX), Keros Therapeutics, Inc. (Nasdaq: KROS), and Terns Pharmaceuticals, Inc. (Nasdaq: TERN), as well as several private companies. Dr. Gordon previously served on the boards of Alector, Inc. (Nasdaq: ALEC), Gemini Therapeutics, Inc. (formerly Nasdaq: GMTX which merged with Disc Medicine, Inc.), Kinnate Biopharma Inc. (Nasdaq: KNTE), ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), Passage Bio, Inc. (Nasdaq: PASG), Prevail Therapeutics Inc. (formerly Nasdaq: PRVL which was acquired by Eli Lilly), SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), Theseus Pharmaceuticals, Inc. (formerly Nasdaq: THRX which was acquired by Concentra Biosciences LLC), and Turning Point Therapeutics, Inc. (formerly Nasdaq: TPTX which was acquired by Bristol Myers Squibb Co.). Dr. Gordon received his B.A. in Chemistry from Harvard College, his Ph.D. in Molecular Biology from the Massachusetts Institute of Technology, and was a Fellow at The Rockefeller University.
- Jasbir Seehra
-
Jasbir Seehra自2015年12月以来一直担任我们的首席执行官和董事会成员。在加入我们之前，Seehra博士于2011年12月至2015年4月担任Ember Therapeutics，Inc.的首席科学官。2004年2月至2010年11月，Seehra博士担任Acceleron PharmaInc.的联合创始人兼首席科学官Seehra博士担任EloxxPharmaceuticals，Inc.董事会成员他也曾担任Wyeth Pharmaceuticals Inc.的生物化学Vice President，并领导Genetics Institute，Inc.的小分子铅发现工作，在那里他帮助建立了该研究所的小分子药物发现能力，包括药物化学、高通量筛选和结构生物学。Seehra博士获得了理学学士学位。以及英国南安普顿大学（University of Southampton）生物化学博士学位。他在麻省理工学院（Massachusetts Institute of Technology）完成博士后工作。
Jasbir Seehra has served as a member of Board since February 2018. Dr. Seehra has served as Chief Executive Officer and a member of the board of directors of Keros Therapeutics since December 2015. Before that, he worked for Third Rock Ventures and helped establish Decibel where he still serves on their Scientific Advisory Board and Ember Therapeutics (as Chief Scientific Officer). Before joining Ember, Dr. Seehra was part of a team of scientific advisors for many companies. He has served as an advisor on Ember's Scientific Advisory Board since the company's launch. With more than 25 years of experience developing innovative small molecule and biologic drugs, Dr. Seehra served as Chief Scientific Officer of Acceleron Pharma, Inc., which he co-founded in 2003. He has also served as Vice President of Biological Chemistry at Wyeth and led the small molecule lead discovery effort at Genetics Institute, Inc., where he successfully built the institute's small molecule drug discovery capabilities, including medicinal chemistry, high throughput screening and structural biology. Dr. Seehra has authored numerous publications and is an inventor on 78 patents. Dr. Seehra received a B.S. and a Ph.D. in Biochemistry from the University of Southampton in England. He completed his postdoctoral work at the Massachusetts Institute of Technology. - Jasbir Seehra自2015年12月以来一直担任我们的首席执行官和董事会成员。在加入我们之前，Seehra博士于2011年12月至2015年4月担任Ember Therapeutics，Inc.的首席科学官。2004年2月至2010年11月，Seehra博士担任Acceleron PharmaInc.的联合创始人兼首席科学官Seehra博士担任EloxxPharmaceuticals，Inc.董事会成员他也曾担任Wyeth Pharmaceuticals Inc.的生物化学Vice President，并领导Genetics Institute，Inc.的小分子铅发现工作，在那里他帮助建立了该研究所的小分子药物发现能力，包括药物化学、高通量筛选和结构生物学。Seehra博士获得了理学学士学位。以及英国南安普顿大学（University of Southampton）生物化学博士学位。他在麻省理工学院（Massachusetts Institute of Technology）完成博士后工作。
- Jasbir Seehra has served as a member of Board since February 2018. Dr. Seehra has served as Chief Executive Officer and a member of the board of directors of Keros Therapeutics since December 2015. Before that, he worked for Third Rock Ventures and helped establish Decibel where he still serves on their Scientific Advisory Board and Ember Therapeutics (as Chief Scientific Officer). Before joining Ember, Dr. Seehra was part of a team of scientific advisors for many companies. He has served as an advisor on Ember's Scientific Advisory Board since the company's launch. With more than 25 years of experience developing innovative small molecule and biologic drugs, Dr. Seehra served as Chief Scientific Officer of Acceleron Pharma, Inc., which he co-founded in 2003. He has also served as Vice President of Biological Chemistry at Wyeth and led the small molecule lead discovery effort at Genetics Institute, Inc., where he successfully built the institute's small molecule drug discovery capabilities, including medicinal chemistry, high throughput screening and structural biology. Dr. Seehra has authored numerous publications and is an inventor on 78 patents. Dr. Seehra received a B.S. and a Ph.D. in Biochemistry from the University of Southampton in England. He completed his postdoctoral work at the Massachusetts Institute of Technology.
- Nima Farzan
-
Nima Farzan自2020年3月起担任我们的总裁兼首席执行官，并担任我们的董事会成员。Farzan先生还于2020年2月至2020年3月担任风险投资基金Foresite Capital的常驻高管。2018年10月至2020年3月，Farzan先生曾担任多家生命科学公司的顾问，包括Emergent BiosolutionsInc.和Moda Pharmaceuticals。在加入我们之前，Farzan先生曾在Paxvax，Inc.（现为生物制药公司Emergent BiosolutionsInc.的一部分）任职，最初于2011年9月至2018年10月担任首席运营官，随后担任首席执行官兼总裁。从2004年8月到2011年9月，他曾担任Novartis AG公司（制药公司）的多种职务，包括Novartis Vaccines and Diagnostics公司（诺华公司的一个部门）的副总裁、代谢疾病全球项目主管和美国营销副总裁。Farzan先生目前在KerosTherapeutics，Inc.（纳斯达克市场代码:KROS）的董事会任职。Farzan先生拥有斯坦福大学（Stanford University）人类生物学学士学位和哈佛商学院（Harvard Business School）工商管理硕士学位。
Nima Farzan has served as President and Chief Executive Officer and as a member of board of directors since March 2020. Mr. Farzan has also served as an Executive in Residence at Foresite Capital, a venture capital fund, from February 2020 to March 2020. From October 2018 to March 2020 Mr. Farzan worked as an advisor to various life sciences companies, including Emergent BioSolutions Inc. and MODA Pharmaceuticals. Prior to joining us, Mr. Farzan was with PaxVax, Inc. now part of Emergent BioSolutions Inc., a biopharmaceutical company, where he served initially as Chief Operating Officer and then Chief Executive Officer and President from September 2011 to October 2018. From August 2004 to September 2011 he served in a number of roles at Novartis AG a pharmaceutical company, including VP, Global Program Head for Metabolic Disease and VP, US Marketing at Novartis Vaccines and Diagnostics, a division of Novartis. Mr. Farzan currently serves on the board of directors of Keros Therapeutics, Inc. (Nasdaq: KROS). Mr. Farzan holds a B.A. in Human Biology from Stanford University and an M.B.A. from Harvard Business School. - Nima Farzan自2020年3月起担任我们的总裁兼首席执行官，并担任我们的董事会成员。Farzan先生还于2020年2月至2020年3月担任风险投资基金Foresite Capital的常驻高管。2018年10月至2020年3月，Farzan先生曾担任多家生命科学公司的顾问，包括Emergent BiosolutionsInc.和Moda Pharmaceuticals。在加入我们之前，Farzan先生曾在Paxvax，Inc.（现为生物制药公司Emergent BiosolutionsInc.的一部分）任职，最初于2011年9月至2018年10月担任首席运营官，随后担任首席执行官兼总裁。从2004年8月到2011年9月，他曾担任Novartis AG公司（制药公司）的多种职务，包括Novartis Vaccines and Diagnostics公司（诺华公司的一个部门）的副总裁、代谢疾病全球项目主管和美国营销副总裁。Farzan先生目前在KerosTherapeutics，Inc.（纳斯达克市场代码:KROS）的董事会任职。Farzan先生拥有斯坦福大学（Stanford University）人类生物学学士学位和哈佛商学院（Harvard Business School）工商管理硕士学位。
- Nima Farzan has served as President and Chief Executive Officer and as a member of board of directors since March 2020. Mr. Farzan has also served as an Executive in Residence at Foresite Capital, a venture capital fund, from February 2020 to March 2020. From October 2018 to March 2020 Mr. Farzan worked as an advisor to various life sciences companies, including Emergent BioSolutions Inc. and MODA Pharmaceuticals. Prior to joining us, Mr. Farzan was with PaxVax, Inc. now part of Emergent BioSolutions Inc., a biopharmaceutical company, where he served initially as Chief Operating Officer and then Chief Executive Officer and President from September 2011 to October 2018. From August 2004 to September 2011 he served in a number of roles at Novartis AG a pharmaceutical company, including VP, Global Program Head for Metabolic Disease and VP, US Marketing at Novartis Vaccines and Diagnostics, a division of Novartis. Mr. Farzan currently serves on the board of directors of Keros Therapeutics, Inc. (Nasdaq: KROS). Mr. Farzan holds a B.A. in Human Biology from Stanford University and an M.B.A. from Harvard Business School.
- Julius Knowles
-
Julius Knowles自2016年4月以来一直担任我们的董事会成员。自2014年1月以来，Knowles先生一直担任Partners Innovation Fund（Partners梦百合的风险部门）的合伙人。2012年3月至2014年1月，Knowles先生担任被JunoTherapeutics，Inc.收购的X-Body Biosciences Inc.的首席执行官。Knowles从2006年10月到2012年2月在Novartis负责全球技术和药物发现合作，包括担任Novartis Institute of Biomedical Research战略联盟平台团队主管。从2002年3月到2006年6月，Knowles先生担任Novalar Pharmaceuticals，Inc.的总裁。2001年6月至2002年3月，Knowles先生曾担任Novacea，Inc.（被Transcept Pharmaceuticals，Inc.收购）的业务发展Vice President，该公司是SGX Pharmaceuticals业务发展Vice President，1999年10月至2001年6月，担任Vertex Pharmaceuticals，Inc.的研究与开发规划总监。Knowles先生还在几家私人生命科学公司的董事会任职。Knowles先生在卡尔顿学院（Carleton College）获得化学学士学位，在宾夕法尼亚大学（University of Pennsylvania）获得工商管理硕士学位和理学硕士学位。加州大学伯克利分校化学学士学位。
Julius Knowles has served as a member of board of directors since April 2016. Since January 2014 Mr. Knowles has served as a Partner at Partners Innovation Fund, the venture arm of Partners HealthCare. From March 2012 to January 2014 Mr. Knowles served as the Chief Executive Officer of X-BODY BioSciences Inc. acquired by Juno Therapeutics, Inc.. From October 2006 to February 2012 Mr. Knowles was responsible for global technology and drug discovery collaborations at Novartis, including as the Head of the Platforms team for Strategic Alliances at Novartis Institute of Biomedical Research. From March 2002 to June 2006 Mr. Knowles served as the President of Novalar Pharmaceuticals, Inc. Mr. Knowles previously served as the Vice President of Business Development of Novacea, Inc. (acquired by Transcept Pharmaceuticals, Inc.) from June 2001 to March 2002 the Vice President of Business Development of SGX Pharmaceuticals, Inc. from October 1999 to June 2001 and the Director of Research and Development Planning at Vertex Pharmaceuticals, Inc. from June 1993 to October 1999. Mr. Knowles also serves on the board of several private life science companies. Mr. Knowles received a B.A. with distinction in Chemistry from Carleton College, an M.B.A. from the University of Pennsylvania and an M.Sc. in Chemistry from UC Berkeley. - Julius Knowles自2016年4月以来一直担任我们的董事会成员。自2014年1月以来，Knowles先生一直担任Partners Innovation Fund（Partners梦百合的风险部门）的合伙人。2012年3月至2014年1月，Knowles先生担任被JunoTherapeutics，Inc.收购的X-Body Biosciences Inc.的首席执行官。Knowles从2006年10月到2012年2月在Novartis负责全球技术和药物发现合作，包括担任Novartis Institute of Biomedical Research战略联盟平台团队主管。从2002年3月到2006年6月，Knowles先生担任Novalar Pharmaceuticals，Inc.的总裁。2001年6月至2002年3月，Knowles先生曾担任Novacea，Inc.（被Transcept Pharmaceuticals，Inc.收购）的业务发展Vice President，该公司是SGX Pharmaceuticals业务发展Vice President，1999年10月至2001年6月，担任Vertex Pharmaceuticals，Inc.的研究与开发规划总监。Knowles先生还在几家私人生命科学公司的董事会任职。Knowles先生在卡尔顿学院（Carleton College）获得化学学士学位，在宾夕法尼亚大学（University of Pennsylvania）获得工商管理硕士学位和理学硕士学位。加州大学伯克利分校化学学士学位。
- Julius Knowles has served as a member of board of directors since April 2016. Since January 2014 Mr. Knowles has served as a Partner at Partners Innovation Fund, the venture arm of Partners HealthCare. From March 2012 to January 2014 Mr. Knowles served as the Chief Executive Officer of X-BODY BioSciences Inc. acquired by Juno Therapeutics, Inc.. From October 2006 to February 2012 Mr. Knowles was responsible for global technology and drug discovery collaborations at Novartis, including as the Head of the Platforms team for Strategic Alliances at Novartis Institute of Biomedical Research. From March 2002 to June 2006 Mr. Knowles served as the President of Novalar Pharmaceuticals, Inc. Mr. Knowles previously served as the Vice President of Business Development of Novacea, Inc. (acquired by Transcept Pharmaceuticals, Inc.) from June 2001 to March 2002 the Vice President of Business Development of SGX Pharmaceuticals, Inc. from October 1999 to June 2001 and the Director of Research and Development Planning at Vertex Pharmaceuticals, Inc. from June 1993 to October 1999. Mr. Knowles also serves on the board of several private life science companies. Mr. Knowles received a B.A. with distinction in Chemistry from Carleton College, an M.B.A. from the University of Pennsylvania and an M.Sc. in Chemistry from UC Berkeley.
- Jean Jacques Bienaime
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Mary Ann Gray
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Alpna Seth
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
高管简历
中英对照 | 中文 | 英文- Jasbir Seehra
Jasbir Seehra自2015年12月以来一直担任我们的首席执行官和董事会成员。在加入我们之前，Seehra博士于2011年12月至2015年4月担任Ember Therapeutics，Inc.的首席科学官。2004年2月至2010年11月，Seehra博士担任Acceleron PharmaInc.的联合创始人兼首席科学官Seehra博士担任EloxxPharmaceuticals，Inc.董事会成员他也曾担任Wyeth Pharmaceuticals Inc.的生物化学Vice President，并领导Genetics Institute，Inc.的小分子铅发现工作，在那里他帮助建立了该研究所的小分子药物发现能力，包括药物化学、高通量筛选和结构生物学。Seehra博士获得了理学学士学位。以及英国南安普顿大学（University of Southampton）生物化学博士学位。他在麻省理工学院（Massachusetts Institute of Technology）完成博士后工作。
Jasbir Seehra has served as a member of Board since February 2018. Dr. Seehra has served as Chief Executive Officer and a member of the board of directors of Keros Therapeutics since December 2015. Before that, he worked for Third Rock Ventures and helped establish Decibel where he still serves on their Scientific Advisory Board and Ember Therapeutics (as Chief Scientific Officer). Before joining Ember, Dr. Seehra was part of a team of scientific advisors for many companies. He has served as an advisor on Ember's Scientific Advisory Board since the company's launch. With more than 25 years of experience developing innovative small molecule and biologic drugs, Dr. Seehra served as Chief Scientific Officer of Acceleron Pharma, Inc., which he co-founded in 2003. He has also served as Vice President of Biological Chemistry at Wyeth and led the small molecule lead discovery effort at Genetics Institute, Inc., where he successfully built the institute's small molecule drug discovery capabilities, including medicinal chemistry, high throughput screening and structural biology. Dr. Seehra has authored numerous publications and is an inventor on 78 patents. Dr. Seehra received a B.S. and a Ph.D. in Biochemistry from the University of Southampton in England. He completed his postdoctoral work at the Massachusetts Institute of Technology.- Jasbir Seehra自2015年12月以来一直担任我们的首席执行官和董事会成员。在加入我们之前，Seehra博士于2011年12月至2015年4月担任Ember Therapeutics，Inc.的首席科学官。2004年2月至2010年11月，Seehra博士担任Acceleron PharmaInc.的联合创始人兼首席科学官Seehra博士担任EloxxPharmaceuticals，Inc.董事会成员他也曾担任Wyeth Pharmaceuticals Inc.的生物化学Vice President，并领导Genetics Institute，Inc.的小分子铅发现工作，在那里他帮助建立了该研究所的小分子药物发现能力，包括药物化学、高通量筛选和结构生物学。Seehra博士获得了理学学士学位。以及英国南安普顿大学（University of Southampton）生物化学博士学位。他在麻省理工学院（Massachusetts Institute of Technology）完成博士后工作。
- Jasbir Seehra has served as a member of Board since February 2018. Dr. Seehra has served as Chief Executive Officer and a member of the board of directors of Keros Therapeutics since December 2015. Before that, he worked for Third Rock Ventures and helped establish Decibel where he still serves on their Scientific Advisory Board and Ember Therapeutics (as Chief Scientific Officer). Before joining Ember, Dr. Seehra was part of a team of scientific advisors for many companies. He has served as an advisor on Ember's Scientific Advisory Board since the company's launch. With more than 25 years of experience developing innovative small molecule and biologic drugs, Dr. Seehra served as Chief Scientific Officer of Acceleron Pharma, Inc., which he co-founded in 2003. He has also served as Vice President of Biological Chemistry at Wyeth and led the small molecule lead discovery effort at Genetics Institute, Inc., where he successfully built the institute's small molecule drug discovery capabilities, including medicinal chemistry, high throughput screening and structural biology. Dr. Seehra has authored numerous publications and is an inventor on 78 patents. Dr. Seehra received a B.S. and a Ph.D. in Biochemistry from the University of Southampton in England. He completed his postdoctoral work at the Massachusetts Institute of Technology.
- Keith Regnante
Keith Regnante自2020年2月起担任我们的首席财务官。在加入我们之前，Regnante先生于2016年8月至2020年1月担任Wave Life SciencesLtd.首席财务官2014年2月至2016年8月，雷南特先生担任全球生物制药公司Shire Pharmaceuticals或Shire的财务Vice President。在Shire任职期间，Regnante先生还曾在财务领导团队和研发领导团队任职。2013年9月至2014年2月，他担任ARIADPharmaceuticals，Inc.研发财务主管从1999年1月到2013年8月，Regnante先生在BiogenInc.担任多个财务职位，包括从2011年到2013年担任公司财务高级总监，从2008年到2011年担任全球研发财务高级总监，以及从1999年开始担任其他几个职位。在担任这些职务之前，Regnante先生在波士顿咨询集团（Boston Consulting Group）担任顾问。他持有Tufts University的经济学学士学位，以及the MIT Sloan School of Management的工商管理硕士学位。
Keith Regnante has served as Chief Financial Officer since February 2020. Prior to joining, from August 2016 to January 2020 Mr. Regnante served as Chief Financial Officer at Wave Life Sciences Ltd. From February 2014 to August 2016 Mr. Regnante served as Vice President of Finance at Shire Pharmaceuticals, or Shire, a global biopharmaceutical company. Mr. Regnante also served on the Financial Leadership Team and the R&D Leadership Team while he was at Shire. From September 2013 to February 2014 he served as Head of R&D Finance for ARIAD Pharmaceuticals, Inc. From January 1999 to August 2013 Mr. Regnante held multiple finance positions at Biogen Inc., including Senior Director of Corporate Finance from 2011 to 2013 Senior Director of Worldwide R&D Finance from 2008 to 2011 and several other positions dating back to 1999. Prior to these roles, Mr. Regnante worked as a consultant at The Boston Consulting Group. He holds a B.A. in Economics from Tufts University and an M.B.A. from the MIT Sloan School of Management.- Keith Regnante自2020年2月起担任我们的首席财务官。在加入我们之前，Regnante先生于2016年8月至2020年1月担任Wave Life SciencesLtd.首席财务官2014年2月至2016年8月，雷南特先生担任全球生物制药公司Shire Pharmaceuticals或Shire的财务Vice President。在Shire任职期间，Regnante先生还曾在财务领导团队和研发领导团队任职。2013年9月至2014年2月，他担任ARIADPharmaceuticals，Inc.研发财务主管从1999年1月到2013年8月，Regnante先生在BiogenInc.担任多个财务职位，包括从2011年到2013年担任公司财务高级总监，从2008年到2011年担任全球研发财务高级总监，以及从1999年开始担任其他几个职位。在担任这些职务之前，Regnante先生在波士顿咨询集团（Boston Consulting Group）担任顾问。他持有Tufts University的经济学学士学位，以及the MIT Sloan School of Management的工商管理硕士学位。
- Keith Regnante has served as Chief Financial Officer since February 2020. Prior to joining, from August 2016 to January 2020 Mr. Regnante served as Chief Financial Officer at Wave Life Sciences Ltd. From February 2014 to August 2016 Mr. Regnante served as Vice President of Finance at Shire Pharmaceuticals, or Shire, a global biopharmaceutical company. Mr. Regnante also served on the Financial Leadership Team and the R&D Leadership Team while he was at Shire. From September 2013 to February 2014 he served as Head of R&D Finance for ARIAD Pharmaceuticals, Inc. From January 1999 to August 2013 Mr. Regnante held multiple finance positions at Biogen Inc., including Senior Director of Corporate Finance from 2011 to 2013 Senior Director of Worldwide R&D Finance from 2008 to 2011 and several other positions dating back to 1999. Prior to these roles, Mr. Regnante worked as a consultant at The Boston Consulting Group. He holds a B.A. in Economics from Tufts University and an M.B.A. from the MIT Sloan School of Management.
- Lorena Lerner
Lorena Lerner，自2024年1月起担任公司高级副总裁，研究。在此之前，勒纳博士担任公司副总裁，研究始于2022年5月。2017年9月至2022年5月，勒纳博士在Oncorus, Inc.担任多个职务，职责不断增加，包括2017年9月至2018年12月分子生物学高级总监、2019年1月至2021年11月分子生物学副总裁以及2021年12月至2022年5月研究副总裁。在加入Oncorus, Inc.之前，Lerner博士曾于2016年至2017年在Quiet Therapeutics工作，于2015年至2016年在Scholar Rock Holding Corporation工作，于2003年至2015年在AVEO制药，Inc.工作。勒纳博士在布宜诺斯艾利斯大学获得分子生物学硕士学位和生物化学博士学位。她在洛克菲勒大学完成了博士后工作。
Lorena Lerner,has served as the Company's Senior Vice President, Research since January 2024. Prior to that, Dr. Lerner served as the Company's Vice President, Research beginning in May 2022. From September 2017 to May 2022, Dr. Lerner held multiple positions of increasing responsibility at Oncorus, Inc., including Senior Director, Molecular Biology from September 2017 to December 2018, Vice President, Molecular Biology from January 2019 to November 2021 and Vice President, Research from December 2021 to May 2022. Prior to Oncorus, Inc., Dr. Lerner worked at Quiet Therapeutics from 2016 to 2017, at Scholar Rock Holding Corporation from 2015 to 2016 and at AVEO Pharmaceuticals, Inc. from 2003 to 2015. Dr. Lerner received an M.S. in Molecular Biology and a Ph.D. in Biochemistry from the University of Buenos Aires. She completed her postdoctoral work at The Rockefeller University.- Lorena Lerner，自2024年1月起担任公司高级副总裁，研究。在此之前，勒纳博士担任公司副总裁，研究始于2022年5月。2017年9月至2022年5月，勒纳博士在Oncorus, Inc.担任多个职务，职责不断增加，包括2017年9月至2018年12月分子生物学高级总监、2019年1月至2021年11月分子生物学副总裁以及2021年12月至2022年5月研究副总裁。在加入Oncorus, Inc.之前，Lerner博士曾于2016年至2017年在Quiet Therapeutics工作，于2015年至2016年在Scholar Rock Holding Corporation工作，于2003年至2015年在AVEO制药，Inc.工作。勒纳博士在布宜诺斯艾利斯大学获得分子生物学硕士学位和生物化学博士学位。她在洛克菲勒大学完成了博士后工作。
- Lorena Lerner,has served as the Company's Senior Vice President, Research since January 2024. Prior to that, Dr. Lerner served as the Company's Vice President, Research beginning in May 2022. From September 2017 to May 2022, Dr. Lerner held multiple positions of increasing responsibility at Oncorus, Inc., including Senior Director, Molecular Biology from September 2017 to December 2018, Vice President, Molecular Biology from January 2019 to November 2021 and Vice President, Research from December 2021 to May 2022. Prior to Oncorus, Inc., Dr. Lerner worked at Quiet Therapeutics from 2016 to 2017, at Scholar Rock Holding Corporation from 2015 to 2016 and at AVEO Pharmaceuticals, Inc. from 2003 to 2015. Dr. Lerner received an M.S. in Molecular Biology and a Ph.D. in Biochemistry from the University of Buenos Aires. She completed her postdoctoral work at The Rockefeller University.
- Esther Cho
Esther Cho，自2023年2月起担任Keros Therapeutics, Inc.高级副总裁、总法律顾问，并担任Keros Therapeutics, Inc.秘书。在此之前，Cho女士于2020年4月开始担任Keros Therapeutics, Inc.法律主管。在加入Keros Therapeutics, Inc.之前，Cho女士是Cooley LLP的一名合伙人，在那里她代表生命科学公司处理生命周期各个阶段的各种事务。赵女士获得了波士顿大学法学院的法学博士学位和宾夕法尼亚大学的历史学学士学位。
Esther Cho,has served as Keros Therapeutics, Inc. Senior Vice President, General Counsel since February 2023, and also serves as Keros Therapeutics, Inc. Secretary. Prior to that, Ms. Cho served as Keros Therapeutics, Inc. Head of Legal beginning in April 2020. Prior to joining Keros Therapeutics, Inc. , Ms. Cho was an associate at Cooley LLP, where she represented life science companies in a wide variety of matters through all stages of their life cycle. Ms. Cho received a J.D. from Boston University School of Law and a B.A. in History from University of Pennsylvania.- Esther Cho，自2023年2月起担任Keros Therapeutics, Inc.高级副总裁、总法律顾问，并担任Keros Therapeutics, Inc.秘书。在此之前，Cho女士于2020年4月开始担任Keros Therapeutics, Inc.法律主管。在加入Keros Therapeutics, Inc.之前，Cho女士是Cooley LLP的一名合伙人，在那里她代表生命科学公司处理生命周期各个阶段的各种事务。赵女士获得了波士顿大学法学院的法学博士学位和宾夕法尼亚大学的历史学学士学位。
- Esther Cho,has served as Keros Therapeutics, Inc. Senior Vice President, General Counsel since February 2023, and also serves as Keros Therapeutics, Inc. Secretary. Prior to that, Ms. Cho served as Keros Therapeutics, Inc. Head of Legal beginning in April 2020. Prior to joining Keros Therapeutics, Inc. , Ms. Cho was an associate at Cooley LLP, where she represented life science companies in a wide variety of matters through all stages of their life cycle. Ms. Cho received a J.D. from Boston University School of Law and a B.A. in History from University of Pennsylvania.